Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

By Jane E. Visvader, G. Lindeman. Nature Reviews. Cancer, 2008

3,532 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/26a901adfd38efb6b0ac6a4d4dfb3ec82e3aa31f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. S. Piccolo
2. M. Nieto
3. Zena Werb
4. M. Cordenonsi
5. V. Plaks
6. Niwen Kong
7. Christophe Klein
8. F. Zanconato

In Molecular Biology

1. R. Weinberg
2. M. Nieto
3. Zena Werb
4. J. P. Thiery
5. S. Piccolo
6. V. Plaks
7. Samy Lamouille
8. Niwen Kong

In Oncology

1. R. Weinberg
2. M. Nieto
3. Zena Werb
4. J. P. Thiery
5. V. Plaks
6. Niwen Kong
7. R. Derynck
8. Jane E. Visvader

Citations in the corpus

• New horizons in tumor microenvironment biology: challenges and opportunities (2015, background): “In such cases, CSCs represent the potential source of eventual tumor relapse following therapy, which are typically therapy-resistant due to decreased oxidative stress response, increased genomic stability, and expression of multiple drug resistance transporters [35].”
• TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progression (2013, background): “CSCs, a small population of self-renewing cells with the ability to initiate tumor formation, are increasingly seen as having a key role in driving cancer progression, as they give rise to heterogeneous cancer cell populations [60,61].”
• Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. (2010, background): “1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy 2Dipartimento di Medicina, Chirurgia ed Odontoiatria, Universita’ degli Studi di Milano, Via di Rudini’ 8, 20122 Milan, Italy 3Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milan, Italy 4These…”
• Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment (2018, background): “Additionally, certain intracellular proteins also have been used as CSCs markers, such as aldehyde dehydrogenase 1 (ALDH1) which is used to characterize CSCs in many types of cancer such as leukemia, breast, colon, liver, lung, pancreas, and so forth [12, 53].”
• The Cancer Stem Cell Niche: How Essential is the Niche in Regulating Stemness of Tumor Cells? (2015, positive): “However, it became increasingly clear that the frequency of CSCs could vary dramatically between tumor types and also between tumors of the same origin (Visvader and Lindeman, 2008).”
• Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “Additional stem cell markers including CD44 [38,121] and CD133 [121] have been associated with drug resistance andmay serve as potential targets for future nanodrugs to eliminate CSCs and prevent recurrence.”
• Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? (2009, background): “Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
• Interactions between cancer stem cells and their niche govern metastatic colonization (2011, background): “Stem cells are suspected to rely on signals from their stromal environment, such as localized growth factors that can affect stem cell maintenance and proliferatio”
• Tumor heterogeneity: causes and consequences (2009, background): “Subsequently, the cancer stem cell concept has been expanded to encompass solid malignancies: the CD44+CD24− subset of human breast cancer cells was shown to be highly enriched for the ability to initiate tumors upon transplantation into mammary fat pads of immunocompromised mice [6], and the existe”
• Cells of origin in cancer (2011, background): “There is considerable evidence that several diverse cancers, both leukaemias and solid tumours, are hierarchically organized and sustained by a subpopulation of self-renewing cells that can generate the full repertoire of tumour cells (both tumorigenic and non-tumorigenic cells”
• Parallel progression of primary tumours and metastases (2009, background): “Cancer stem cells (CSCs) or tumour-propagating cells have usually been isolated from primary tumours and these populations are thought to consist of metastasis founder cell”
• Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients (2009, background): “For epithelial malignancies, the epithelial-mesenchymal transition (EMT) is considered to be the crucial event in the metastatic process, which involves the disruption of epithelial cell homeostasis and the acquisition of a migratory mesenchymal phenotype allowing these cells to travel to the site o”
• Cancer stem cells: current status and evolving complexities. (2012, background): “CSCs were subsequently demonstrated to occur in diverse solid tumors (reviewed in Visvader and Lindeman, 2008).”
• Reactive oxygen species in cancer (2010, background): “CSCs utilize redoxregulatory mechanisms to promote cell survival and tolerance to treatment [219, 220].”